Introduction According to current guidelines (class I recommendation), the treatment of heart failure with reduced ejection fraction (HFrEF) – defined as left ventricular ejection fraction (LVEF) ≤40% – should be based on the quadruple therapy scheme aimed at reducing cardiovascular outcomes. This regimen consists of beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), renin–angiotensin–aldosterone system blockers (including angiotensin-converting enzyme inhibitors ACEIs, Angiotensin II Receptor Blockers ARBs, or Angiotensin Receptor–Neprilysin Inhibitors ARNIs), and Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i)., In recent decades, with the therapeutic ...
Wolf et al. (Wed,) studied this question.